Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, et al. Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988–2012: A Single-institution. High-volume Experience in China Ann Surg. 2016;263:88–95.

Google Scholar 

Moehler M, Högner A, Wagner AD, Obermannova R, Alsina M, Thuss-Patience P, et al. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. Eur J Cancer. 2022;176:13–29.

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, Brown University, et al. (2017) Integrated genomic characterization of oesophageal carcinoma. Nature. 541:169–175.

Geng Q, Lao J, Zuo X, Chen S, Bei JX, Xu D. Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes. J Pathol. 2020;252:263–73.

Article  CAS  PubMed  Google Scholar 

Lin Y, Luo Y, Sun Y, Guo W, Zhao X, Xi Y, et al. Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction. Nat Commun. 2020;11:6091.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, et al. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021;70:2055–65.

Article  CAS  PubMed  Google Scholar 

Dubois F, Sidiropoulos N, Weischenfeldt J, Beroukhim R. Structural variations in cancer and the 3D genome. Nat Rev Cancer. 2022;22:533–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen K, Yang D, Li X, Sun B, Song F, Cao W, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015;112:1107–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020–31.

Article  CAS  PubMed  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haradhvala NJ, Polak P, Stojanov P, Covington KR, Shinbrot E, Hess JM, et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell. 2016;164:538–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bergstrom EN, Huang MN, Mahto U, Barnes M, Stratton MR, Rozen SG, Alexandrov LB. SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. BMC Genomics. 2019;20:685.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578:112–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yicheng G, Yuli G, Yuxiao F, Chengyu Z, Zhiting W, Chi Z, et al. Pan-Peptide Meta Learning for T-cell receptor–antigen binding recognition. Nat Mach Intell. 2023;5:236–49.

Article  Google Scholar 

Springer I, Tickotsky N, Louzoun Y. Contribution of T Cell Receptor Alpha and Beta CDR3, MHC Typing, V and J Genes to Peptide Binding Prediction. Front Immunol. 2021;12: 664514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang T, Joubert P, Ansari-Pour N, Zhao W, Hoang PH, Lokanga R, et al. Genomic and evolutionary classification of lung cancer in never smokers. Nat Genet. 2021;53:1348–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao X, Subramanian S. Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. Pharmacol Ther. 2018;181:76–84.

Article  CAS  PubMed  Google Scholar 

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol. 2021;32:1127–36.

Article  CAS  PubMed  Google Scholar 

Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020;15:1409–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Mattos-Arruda L, Vazquez M, Finotello F, Lepore R, Porta E, Hundal J, et al. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:978–90.

Article  PubMed  Google Scholar 

Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, et al. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. J Immunother Cancer. 2023;11(6):e007104.

Article  PubMed  PubMed Central  Google Scholar 

Ooki A, Osumi H, Yoshino K, Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair. Gastric Cancer. 2024;27:907–31.

Article  PubMed  PubMed Central  Google Scholar 

Porciello N, Franzese O, D’Ambrosio L, Palermo B, Nisticò P. T-cell repertoire diversity: friend or foe for protective antitumor response. J Exp Clin Cancer Res. 2022;41:356.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan C, Ma X, Guo Z, Wei X, Han D, Zhang T, et al. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. Oncoimmunology. 2022;11:2025668.

Article  PubMed  PubMed Central  Google Scholar 

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1–10.

Article  CAS  PubMed  Google Scholar 

Li Q, Wei P, Huang B, Xu Y, Li X, Li Y, et al. MAEL expression links epithelial-mesenchymal transition and stem cell properties in colorectal cancer. Int J Cancer. 2016;139:2502–11.

Article  CAS  PubMed  Google Scholar 

Shi C, Kwong DL, Li X, Wang X, Fang X, Sun L, et al. MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers (Basel). 2022;14(12):2880.

Article  CAS  PubMed  Google Scholar 

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218.

Article  CAS  PubMed  Google Scholar 

Patel MA, Kratz JD, Lubner SJ, Loconte NK, Uboha NV. Esophagogastric cancers: integrating immunotherapy therapy into current practice. J Clin Oncol. 2022;40:2751–62.

Article  CAS  PubMed  PubMed Central